MEDG Medgenics(Regs)

TIDMMEDG TIDMMEDU

RNS Number : 0662I

Medgenics Inc

08 June 2011

Medgenics, Inc.

(the "Company")

Issue of Equity and Director/PDMR Shareholding

8 June 2011

Medgenics, Inc. (NYSE Amex: MDGN and MDGN.W and London Stock Exchange - AIM: MEDG and MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, announces that on May 12, 2011 the Company issued a total of 22,945 new common shares of par value U.S. $0.0001 each in the Company ("Common Shares") and on May 27, 2011 the Company issued 18,269 new Common Shares as a result of exercises of options over and above the remaining capacity available under the Company's existing Block Admission- which exhausted remaining capacity in the six months to June 4, 2011 as announced on June 8, 2011.

This issue of Common Shares includes the issue of 18,269 Common Shares to Gary Brukardt, a director of the Company, following the exercise of 60,507 warrants (with an exercise price of U.S. $2.49 per Common Share) to subscribe for new Common Shares using the cashless exercise mechanism on 27 May 2011. As a result of this exercise of warrants, Gary Brukardt is now interested in a total of 49,880 Common Shares. This holding represents approximately 0.5 per cent of the Company's issued share capital.

In addition to his interest in the Company's common share capital, Mr. Brukardt is interested in the following options and warrants to subscribe for Common Shares:

 
                     % of                                                            % of 
                     Issued                                                          Issued 
             Common  Share                          Expiry      Exercise  Total      Share 
             Shares  Capital  Instrument  Number    Date         Price    Interests  Capital 
-----------  ------  -------  ----------  --------  ----------  --------  ---------  ------- 
Gary 
 Brukardt 
 (Director)  49,880 
-----------  ------  -------  ----------  --------  ----------  --------  ---------  ------- 
                              Options      45,701   18/09/2011  $2.49 
-----------  ------  -------  ----------  --------  ----------  --------  ---------  ------- 
                              Options      26,705   14/11/2012  $7.35 
-----------  ------  -------  ----------  --------  ----------  --------  ---------  ------- 
                              Options      28,571   14/09/2020  $8.19 
-----------  ------  -------  ----------  --------  ----------  --------  ---------  ------- 
                              Options      12,857   12/01/2021  $6.55 
-----------  ------  -------  ----------  --------  ----------  --------  ---------  ------- 
Total        49,880  0.5%                 113,834                         163,714    1.7% 
-----------  ------  -------  ----------  --------  ----------  --------  ---------  ------- 
 
 

Application will been made for the new Common Shares, which rank pari passu with the Company's existing issued share capital, to be admitted to trading on AIM and it is expected that the admission will occur on June 15, 2011.

Following the issue and allotment of the new Common Shares referred to herein and the 170,501 issued under the Company's existing Block Admission, the Company will have a total of 9,631,198 Common Shares in issue and the percentage of shares not in public hands will be 32.9%.

The Company has also made an application for a block admission, in accordance with the AIM Rules, for 1,926,239 Common Shares (in relation to the Company's outstanding warrants and options under its share incentive plans) which represents approximately 20% of the Company's currently issued share capital. It is expected that this block admission will be effective from June 15, 2011.

For further information, contact:

 
Medgenics, Inc.                       Phone: +972 4 902 8900 
 Dr. Andrew L. Pearlman 
Religare Capital Markets (Nominated   Phone: +44 20 7444 0800 
 Adviser) 
 James Pinner 
 Derek Crowhurst 
SVS Securities plc (Joint Broker)     Phone: +44 20 7638 5600 
 Ian Callaway 
Nomura Code Securities PLC (Joint     Phone: +44 20 7776 1219 
 Broker) 
 Jon Senior 
De Facto Financial                    Phone: +44 207 556 1064 
 Mike Wort 
 Anna Dunphy 
Lippert/Heilshorn & Associates, Inc.  Phone: +1 212-838-3777 
 (Investment Relations - US) 
 Anne Marie Fields 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSEAPKPEFPFEEF

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024